ET-600 passes pivotal bioequivalence study; NDA submission expected April 2025

Eton Pharmaceuticals, Inc.

ET-600 (desmopressin oral solution) met primary endpoint in pivotal bioequivalence study of 75 healthy subjects.
Company expects to submit NDA to FDA in April 2025; if approved, would be only FDA-approved oral liquid desmopressin.
CEO Brynjelsen anticipates potential product launch in Q1 2026; pre-launch commercial activities underway.
ET-600 is a proprietary patented formulation for central diabetes insipidus targeting precise pediatric dosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.